Cargando…

Cardiac Dose Predicts the Response to Concurrent Chemoradiotherapy in Esophageal Squamous Cell Carcinoma

SIMPLE SUMMARY: Pursuing a maximal clinical response for esophageal cancer after definitive chemoradiation is crucial, as it may be an integral surrogate endpoint for survival. In addition, radiation dosimetry parameters and treatment-induced inflammation have been validated in terms of survival out...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ho, Yu-Chieh, Lai, Yuan-Chun, Lin, Hsuan-Yu, Ko, Ming-Hui, Wang, Sheng-Hung, Yang, Shan-Jun, Chou, Tsai-Wei, Hung, Li-Chung, Huang, Chia-Chun, Chang, Tung-Hao, Lin, Jhen-Bin, Lin, Jin-Ching
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526131/ https://www.ncbi.nlm.nih.gov/pubmed/37760549 http://dx.doi.org/10.3390/cancers15184580

Ejemplares similares

Low cardiac dose and neutrophil-to-lymphocyte ratio predict overall survival in inoperable esophageal squamous cell cancer patients after chemoradiotherapy
por: Ho, Yu-Chieh, et al.
Publicado: (2021)

Prognostic significance of lung radiation dose in patients with esophageal cancer treated with neoadjuvant chemoradiotherapy
por: Lin, Jhen-Bin, et al.
Publicado: (2019)

Effectiveness of image‐guided radiotherapy for locally advanced esophageal squamous cell carcinoma patients treated with definitive concurrent chemoradiotherapy
por: Kuo, Yao‐Hung, et al.
Publicado: (2019)

A phase II randomized trial comparing neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in advanced squamous cell carcinoma of the pharynx or larynx
por: Huang, Pei-Wei, et al.
Publicado: (2018)

Evaluating the optimal radiation dose for definitive chemoradiotherapy for esophageal squamous cell carcinoma: A single institution experience
por: Ke, Te-Min, et al.
Publicado: (2018)

Oral glutamine supplements reduce concurrent chemoradiotherapy-induced esophagitis in patients with advanced non-small cell lung cancer
por: Chang, Shih-Chieh, et al.
Publicado: (2019)

The crucial role of blood VEGF kinetics in patients with locally advanced esophageal squamous cell carcinoma receiving curative concurrent chemoradiotherapy
por: Chen, Yen-Hao, et al.
Publicado: (2018)

High vs. low radiotherapy dose in locally advanced esophageal squamous cell carcinoma patients treated with neoadjuvant concurrent chemoradiotherapy: an endemic area population-based study
por: Li, Chia-Chin, et al.
Publicado: (2022)

Clinical Significance of Frailty on Treatment Outcome in Nongeriatric Patients With Head and Neck Cancer and Esophageal Cancer Undergoing Curative-Intent Concurrent Chemoradiotherapy
por: Chou, Wen-Chi, et al.
Publicado: (2022)

Consolidative chemotherapy after definitive concurrent chemoradiotherapy for esophageal squamous cell carcinoma patients: a population based cohort study
por: Lin, Chen-Yuan, et al.
Publicado: (2022)

SDF-1α predicts poor prognosis in patients with locally advanced esophageal squamous cell carcinoma receiving definitive concurrent chemoradiotherapy
por: Chen, Yen-Hao, et al.
Publicado: (2022)

The Clinical Outcomes of Locally Advanced Cervical Esophageal Squamous Cell Carcinoma Patients Receiving Curative Concurrent Chemoradiotherapy: A Population-Based Propensity Score-Matched Analysis
por: Chen, Yen-Hao, et al.
Publicado: (2019)

Optimal radiotherapy dose in cervical esophageal squamous cell carcinoma patients treated with definitive concurrent chemoradiotherapy: A population based study
por: Li, Chia‐Chin, et al.
Publicado: (2021)

Neoadjuvant vs definitive concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma patients
por: Chen, Chih-Yi, et al.
Publicado: (2018)

Upregulated Ubiquitin D is a Favorable Prognostic Indicator for Rectal Cancer Patients Undergoing Preoperative Concurrent Chemoradiotherapy
por: Chou, Chia-Lin, et al.
Publicado: (2022)

Treatment Outcomes of Patients with Locally Advanced Synchronous Esophageal and Head/Neck Squamous Cell Carcinoma Receiving Curative Concurrent Chemoradiotherapy
por: Chen, Yen-Hao, et al.
Publicado: (2017)

Concurrent chemoradiotherapy with S-1 compared with concurrent chemoradiotherapy with docetaxel and cisplatin for locally advanced esophageal squamous cell carcinoma
por: Zhou, Xi-Lei, et al.
Publicado: (2021)

Efficacy of Different Chemotherapy Regimens in Patients with Locally Advanced Synchronous Esophageal and Head/Neck Squamous Cell Carcinoma Receiving Curative Concurrent Chemoradiotherapy
por: Chen, Yen-Hao, et al.
Publicado: (2020)

Concurrent Chemoradiotherapy-Driven Cell Plasticity by miR-200 Family Implicates the Therapeutic Response of Esophageal Squamous Cell Carcinoma
por: Lee, Yu-Cheng, et al.
Publicado: (2022)

Pretreatment carcinoembryonic antigen level is a risk factor for para-aortic lymph node recurrence in addition to squamous cell carcinoma antigen following definitive concurrent chemoradiotherapy for squamous cell carcinoma of the uterine cervix
por: Huang, Eng-Yen, et al.
Publicado: (2012)

Overexpression of Dehydrogenase/Reductase 9 Predicts Poor Response to Concurrent Chemoradiotherapy and Poor Prognosis in Rectal Cancer Patients
por: Chen, Tzu-Ju, et al.
Publicado: (2022)

The prognostic significance of celiac lymph node metastasis in patients with locally advanced esophageal squamous cell carcinoma receiving curative concurrent chemoradiotherapy
por: Chen, Yen-Hao, et al.
Publicado: (2017)

The clinical impact of supraclavicular lymph node metastasis in patients with locally advanced esophageal squamous cell carcinoma receiving curative concurrent chemoradiotherapy
por: Chen, Yen-Hao, et al.
Publicado: (2018)

Inflammation-based prognostic scores predict the prognosis of locally advanced cervical esophageal squamous cell carcinoma patients receiving curative concurrent chemoradiotherapy: a propensity score-matched analysis
por: Wu, Chia-Che, et al.
Publicado: (2018)

Neck Lymph Node Metastasis as A Poor Prognostic Factor in Thoracic Esophageal Squamous Cell Carcinoma Patients Receiving Concurrent Chemoradiotherapy: A Propensity Score-Matched Analysis
por: Chen, Yen-Hao, et al.
Publicado: (2018)

Maintenance tegafur-plus-uracil after adjuvant concurrent chemoradiotherapy may improve outcome for resected oral cavity squamous cell carcinoma with extranodal extension
por: Huang, Pei-Wei, et al.
Publicado: (2022)

Adjuvant Chemoradiotherapy Associated with Improved Overall Survival in Resected Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy in Intensity-Modulated Radiotherapy Era
por: Yap, Wing-Keen, et al.
Publicado: (2022)

Effectiveness evaluation of adjuvant concurrent chemoradiotherapy for patients with positron emission tomography‐staged esophageal squamous cell carcinoma after complete resection: A population‐based cohort study
por: Fang, Hsin‐Yuan, et al.
Publicado: (2022)

The Impact of Radiotherapy Dose in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Receiving Preoperative Chemoradiotherapy
por: Lo, Chien-Ming, et al.
Publicado: (2021)

MRI Radiomics for Predicting Survival in Patients with Locally Advanced Hypopharyngeal Cancer Treated with Concurrent Chemoradiotherapy
por: Siow, Tiing Yee, et al.
Publicado: (2022)

Cost‐effectiveness of neoadjuvant concurrent chemoradiotherapy versus esophagectomy for locally advanced esophageal squamous cell carcinoma: A population‐based matched case‐control study
por: Lin, Chen‐Yuan, et al.
Publicado: (2015)

Prognostic Value of Lymph Node-To-Primary Tumor Standardized Uptake Value Ratio in Esophageal Squamous Cell Carcinoma Treated with Definitive Chemoradiotherapy
por: Lin, Chia-Hsin, et al.
Publicado: (2020)

MiR-193a-5p/ERBB2 act as concurrent chemoradiation therapy response indicator of esophageal squamous cell carcinoma
por: Lin, Cheng-Han, et al.
Publicado: (2016)

Dynamic Contrast-Enhanced MR Imaging Predicts Local Control in Oropharyngeal or Hypopharyngeal Squamous Cell Carcinoma Treated with Chemoradiotherapy
por: Ng, Shu-Hang, et al.
Publicado: (2013)

Chemotherapy alone versus definitive concurrent chemoradiotherapy for cT4b esophageal squamous cell carcinoma: a population-based study
por: Li, Chia-Chin, et al.
Publicado: (2021)

The Impact of Weight Loss during Chemoradiotherapy for Unresectable Esophageal Cancer: Real-World Results
por: Huang, Tzu-Ting, et al.
Publicado: (2022)

Value of (18)F-FDG PET/CT for Assessment of Advanced Lacrimal Sac Non-Keratinizing Squamous Cell Carcinoma Successfully Treated with Concurrent Chemoradiotherapy
por: Liao, Ching-Yu, et al.
Publicado: (2021)

Concurrent chemoradiotherapy with raltitrexed and nedaplatin regimen for esophageal squamous cell carcinoma
por: Qiu, Xiangnan, et al.
Publicado: (2020)

Propensity score analysis comparing survival between definitive chemoradiotherapy and esophagectomy with adjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma
por: Chang, Yi-Lin, et al.
Publicado: (2022)

A phase II study of concurrent chemoradiotherapy and erlotinib for inoperable esophageal squamous cell carcinoma
por: Zhao, Chuanhua, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_0t8inaqb1b7tit1khrel0v774h